Advertisement
Advertisement
PHAR
Pharming Group N.V. ADS, each representing 10 ordinary shares
10.95
USDSponsored
+0.10
+0.92%
Aug 07, 15:59 UTC -4
Closed
After-Market
10.85
-0.10
-0.91%
PHAR Earnings Reports
Positive Surprise Ratio
PHAR beat 20 of 42 last estimates.
48%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$109.75M
/$0.02
Implied change from Q2 26 (Revenue/ EPS)
+21.67%
/--
Implied change from Q3 25 (Revenue/ EPS)
+12.79%
/+100.00%
Pharming Group N.V. ADS, each representing 10 ordinary shares earnings per share and revenue
On Jul 30, 2026, PHAR reported earnings of 0.00 USD per share (EPS) for Q2 26, missing the estimate of 0.02 USD, resulting in a -90.05% surprise. Revenue reached 90.20 million, compared to an expected 103.64 million, with a -12.97% difference. The market reacted with a -10.49% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 0.02 USD, with revenue projected to reach 109.75 million USD, implying an -- of --% EPS, and increase of 21.67% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Pharming Group N.V. ADS, each representing 10 ordinary shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Pharming Group N.V. ADS, each representing 10 ordinary shares reported EPS of $0.00, missing estimates by -90.05%, and revenue of $90.20M, -12.97% below expectations.
How did the market react to Pharming Group N.V. ADS, each representing 10 ordinary shares's Q2 2026 earnings?
The stock price moved down -10.49%, changed from $12.01 before the earnings release to $10.75 the day after.
When is Pharming Group N.V. ADS, each representing 10 ordinary shares expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Pharming Group N.V. ADS, each representing 10 ordinary shares's next earnings report?
Based on 4
analysts, Pharming Group N.V. ADS, each representing 10 ordinary shares is expected to report EPS of $0.02 and revenue of $109.75M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement